Dynamic Technology Lab Private Ltd Has $309,000 Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

by · The Cerbat Gem

Dynamic Technology Lab Private Ltd decreased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 27.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,533 shares of the biotechnology company’s stock after selling 7,436 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Arrowhead Pharmaceuticals were worth $309,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ARWR. Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 138.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Geode Capital Management LLC grew its position in Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after buying an additional 28,193 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock worth $32,220,000 after buying an additional 21,686 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after acquiring an additional 447,456 shares during the period. Institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

ARWR has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $29.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 12th. Piper Sandler increased their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

View Our Latest Analysis on ARWR

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider directly owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 50,000 shares of company stock valued at $1,525,000 in the last quarter. 4.30% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Stock Up 5.7%

ARWR opened at $46.79 on Wednesday. The firm’s 50-day simple moving average is $37.60 and its 200-day simple moving average is $25.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $46.92. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of -36.55 and a beta of 1.27.

Arrowhead Pharmaceuticals Company Profile

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Stories

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).